Date: April 17, 2023
Time: 10:00 AM - 10:45 AM EST
Overview:
This virtual, live activity is designed to be an intimate discussion on a case focused on the management of small cell lung cancer (SCLC). Expert faculty will discuss key considerations for the management of SCLC in a specific treatment context, with a strong emphasis on bringing practical challenges to the faculty for further discussion. Each Oncology On-Call® activity will feature discussion of a different case, with audience members bringing other questions to be addressed.
Target audience:
This educational activity is directed toward medical oncologists, pulmonologists, and radiation oncologists involved in the treatment and management of patients with SCLC. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.
Learning objectives:
- Integrate new treatment standards among patients with extensive-stage SCLC in multiple lines of care and in consideration of key trial evidence as well as patient-specific characteristics
- Assess novel and emerging approaches for the management of patients with extensive-stage and limited-stage SCLC
- Apply strategies to coordinate multidisciplinary care, monitor treatment, and take steps that mitigate the impact of treatment-related toxicities along the SCLC treatment continuum
Benefits of Attending:
- Talk with expert faculty in the management of SCLC
- Bring your challenging questions to case discussions
- Learn how to incorporate the multidisciplinary team into treatment planning for SCLC
Hot Topics:
- Immunotherapy-based combinations
- Second-line chemotherapy
- Adverse events of novel treatment options
- Novel therapies in development
Jacob Sands, MD
Physician
Dana-Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Consultant: AstraZeneca, Blueprint Medicines, Daiichi-Sankyo, Jazz Pharmaceuticals, Medtronic, PharmaMar, Takeda Pharmaceutical Company.
Jared Weiss, MD
Professor of Medicine
Section Chief, Thoracic and Head/Neck Oncology
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
Disclosures: Grant/Research Support: AstraZeneca, G1 Therapeutics. Consultant: AstraZeneca, G1 Therapeutics, Jazz Pharmaceuticals.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®,, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.